Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Pierre J. LeBel who wrote (765)	4/1/1998 7:55:00 PM
From: READE SMITH	Read Replies (1) \| Respond to of 14101

I have a conspiracy theory to account for the long delays in Pennsaid approval. The Health Protection Branch drug review budget is about 50M per year -- not much -- and certainly not enough to fast-track drug reviews. Incredibly, due to cutbacks, about 70% of that budget comes from user pay fees from the MAJOR drug companies. These multinational firms are the ones that stand to lose the most market share from the wide range of current Arthritis drugs, if Pennsaid is approved. A standing commitee composed of bureaucrats and drug executives sets the priorities. Profits -- not public health cost/benefits is the driver here. So why would anyone be surprised if Dimethaid heard nothing while they slowly burned up their capital.? It may be mistrust -- not impatience-- that causes our drift downward.